Disclosed are: a method for the diagnosis of amyotrophic lateral sclerosis (alleviated as 'ALS', hereinafter) in a subject, including the determination of the degree of progression of symptoms and the monitoring of the progression in the patient; and a method for evaluating the effectiveness of a medicinal agent or the like in the treatment of ALS or the like. Specifically disclosed is a method for the diagnosis of ALS in a subject, including the determination of the degree of progression of symptoms and the monitoring of the progression in the patient, which comprises: (a) a step of collecting a sample from the subject; and (b) a step of analyzing prostaglandin D2 and a metabolite thereof in the sample by mass spectrometry or the like and a step of analyzing creatinine in the sample by mass spectrometry or the like. In some embodiments of the process, these substances contained in a sample such as urine and blood collected from an ALS patient or a subject who is suspected to be suffering from ALS are analyzed, whereby the diagnosis including the determination of the degree of progression of symptoms in the patient can be achieved and the progression of the disease can be monitored. Further, the effectiveness of a medicinal agent or the like or a therapy or the like can be evaluated. The urine component may be a substance capable of being measured, such as proteins, metabolites and hormones contained in urine.
METHOD FOR DIAGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY ANALYSIS OF PROSTAGLANDIN D2 AND METABOLITE THEREOF AND CREATININE, METHOD FOR EVALUATION OF EFFECTIVENESS OF MEDICINAL AGENT IN THERAPY, AND SYSTEM FOR ESTIMATION OF TPGDM LEVEL IN URINE